NCT01316861

Efficacy and Safety of Oral Acarbose Treatment in Patients With Type 2 Diabetes Mellitus

A Prospective, Randomized, Multicenter Study of the Efficacy and Safety of Oral Acarbose Treatment in Patients With Type 2 Diabetes Mellitus

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 79 (actual)
• Sponsor: EMS · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The Purpose of This Study is to Evaluate the Efficacy and Safety of Acarbose in Type 2 Diabetic Patients Using Two Different Formulations of Acarbose 50mg.

Detailed description

Study Design: * Multicenter * Phase III * Randomized * Double Blind * Prospective and Comparative * Experiment duration: 105 days * 5 visits * Efficacy * Adverse event

Conditions

• Type 2 Diabetes Mellitus

Interventions

Type	Name	Description
DRUG	EMS Acarbose	EMS Acarbose 50 mg 3 times a day
DRUG	Bayer Acarbose	Bayer Acarbose 50 mg 3 times a day

Timeline

• Start date: 2012-09-01
• Primary completion: 2013-03-01
• Completion: 2013-05-01
• First posted: 2011-03-16
• Last updated: 2013-09-25

Locations

1 site across 1 country: Brazil